Periampullary and duodenal cancer are major causes of morbidity in patients with familial adenomatous polyposis (FAP); capsule endoscopy (CE) might be useful for the detection of small-bowel polyps in ...

Use of the epidermal growth-factor receptor inhibitor erlotinib led to about a 30% reduction in duodenal polyp burden after 6 months of once-weekly treatment for patients with familial adenomatous ...

EIGHTY-FIVE consecutive cases of solitary and multiple adenomatous polyps of the gastrointestinal tract at the Boston City Hospital have been reviewed. Solitary polyps were noted in 58 and multiple ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Familial adenomatous polyposis (FAP) is a hereditary disease which, in addition to a high risk of bowel cancer, also a greatly increased risk of duodenal cancer. At present, the only treatment ...

Tempest Therapeutics, Inc. has announced that the U.S. FDA has granted a "Study May Proceed" letter for their Phase 2 clinical trial of TPST-1495, a novel dual receptor inhibitor aimed at treating ...